Life Science Investing Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing Respira Therapeutics Enters into Agreement with Gossamer Bio Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Life Science Investing Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On?Demand Vardenafil for Pulmonary Hypertension
Life Science Investing Gossamer Bio Announces Presentations at the European Respiratory Society Congress 2025
West High Yield Resources Ltd. Corporate Update: Initial Reclamation Bond Posted, Permit Conditions Advancing, and Construction Pathway Strengthening for 2026
